Epoch Investment Partners Inc. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 33.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 572,661 shares of the biopharmaceutical company’s stock after selling 293,278 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Gilead Sciences were worth $47,514,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd grew its stake in shares of Gilead Sciences by 7.0% during the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 121 shares during the last quarter. McGlone Suttner Wealth Management Inc. boosted its position in Gilead Sciences by 3.6% in the 1st quarter. McGlone Suttner Wealth Management Inc. now owns 3,581 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 124 shares during the last quarter. Pinkerton Retirement Specialists LLC increased its stake in shares of Gilead Sciences by 2.8% in the 1st quarter. Pinkerton Retirement Specialists LLC now owns 4,703 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 129 shares during the period. Heritage Wealth Management LLC raised its position in shares of Gilead Sciences by 54.6% during the fourth quarter. Heritage Wealth Management LLC now owns 368 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 130 shares during the last quarter. Finally, BerganKDV Wealth Management LLC lifted its stake in shares of Gilead Sciences by 41.9% during the first quarter. BerganKDV Wealth Management LLC now owns 440 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 130 shares during the period. 82.33% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 1,485 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $76.90, for a total transaction of $114,196.50. Following the transaction, the insider now owns 29,402 shares of the company’s stock, valued at $2,261,013.80. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief financial officer now owns 107,587 shares in the company, valued at approximately $8,606,960. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 1,485 shares of the company’s stock in a transaction dated Tuesday, June 13th. The shares were sold at an average price of $76.90, for a total transaction of $114,196.50. Following the completion of the transaction, the insider now owns 29,402 shares in the company, valued at approximately $2,261,013.80. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Gilead Sciences Stock Down 0.7 %
Shares of Gilead Sciences stock traded down $0.57 during trading on Tuesday, reaching $76.08. The stock had a trading volume of 1,223,081 shares, compared to its average volume of 5,748,688. The company has a current ratio of 1.02, a quick ratio of 0.91 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $94.80 billion, a price-to-earnings ratio of 17.66, a P/E/G ratio of 0.86 and a beta of 0.37. Gilead Sciences, Inc. has a 52 week low of $61.44 and a 52 week high of $89.74. The stock has a fifty day moving average price of $77.34 and a two-hundred day moving average price of $79.20.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.30). The business had revenue of $6.60 billion during the quarter, compared to the consensus estimate of $6.45 billion. Gilead Sciences had a return on equity of 37.53% and a net margin of 20.03%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $3.00 annualized dividend and a dividend yield of 3.94%. Gilead Sciences’s dividend payout ratio is presently 68.97%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
- Five stocks we like better than Gilead Sciences
- How to Invest in the Healthcare Sector
- 5 Ways to Play Retail that will Profit in 2023
- What is a Special Dividend?
- This Is Why It’s Not Too Late For You To Buy Meta Stock
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Analysts Say GE’s Healthcare Spinoff Has $20 Upside
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.